{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:20:09Z","timestamp":1792408809782,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s10585-011-9398-4","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T21:28:36Z","timestamp":1308346116000},"page":"649-659","source":"Crossref","is-referenced-by-count":45,"title":["Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292"],"prefix":"10.1007","volume":"28","author":[{"given":"Koh","family":"Furugaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Yorozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieko","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Fujimoto-Ohuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,18]]},"reference":[{"issue":"3","key":"9398_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165\u2013176","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"9398_CR2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","volume":"3","author":"VMD Hirsh","year":"2008","unstructured":"Hirsh VMD, Major PPMDF, Lipton AMD et al (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3(3):228\u2013236","journal-title":"J Thorac Oncol"},{"issue":"4","key":"9398_CR3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrd1066","volume":"2","author":"J Dancey","year":"2003","unstructured":"Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2(4):296\u2013313","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"9398_CR4","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1097\/JTO.0b013e31818ddcaa","volume":"3","author":"C-PMD Schneider","year":"2008","unstructured":"Schneider C-PMD, Heigener DMD, Schott-von-Romer KMD et al (2008) Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 3(12):1446\u20131453","journal-title":"J Thorac Oncol"},{"issue":"10","key":"9398_CR5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ncponc0931","volume":"4","author":"M Pan","year":"2007","unstructured":"Pan M, Santamaria M, Wollman DB (2007) CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nat Clin Pract Oncol 4(10):603\u2013607","journal-title":"Nat Clin Pract Oncol"},{"issue":"4","key":"9398_CR6","first-page":"527","volume":"18","author":"Y Okano","year":"2008","unstructured":"Okano Y, Nishio M (2008) Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis. Clin Calcium 18(4):527\u2013533","journal-title":"Clin Calcium"},{"issue":"3","key":"9398_CR7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","volume":"466","author":"H Sugiura","year":"2008","unstructured":"Sugiura H, Yamada K, Sugiura T et al (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466(3):729\u2013736","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"9398_CR8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.lungcan.2007.11.002","volume":"60","author":"G Zampa","year":"2008","unstructured":"Zampa G, Moscato M, Brannigan BW et al (2008) Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer 60(3):452\u2013454","journal-title":"Lung Cancer"},{"issue":"1","key":"9398_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12032-008-9082-y","volume":"26","author":"H Satoh","year":"2009","unstructured":"Satoh H, Ishikawa H, Ohara G et al (2009) Prolonged response to gefitinib in bone metastasis. Med Oncol 26(1):101\u2013102","journal-title":"Med Oncol"},{"issue":"3","key":"9398_CR10","first-page":"1200","volume":"9","author":"S-J Kim","year":"2003","unstructured":"Kim S-J, Uehara H, Karashima T et al (2003) Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9(3):1200\u20131210","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9398_CR11","first-page":"2940","volume":"63","author":"KL Weber","year":"2003","unstructured":"Weber KL, Doucet M, Price JE et al (2003) Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63(11):2940\u20132947","journal-title":"Cancer Res"},{"issue":"1","key":"9398_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1677\/erc.1.01100","volume":"13","author":"A Angelucci","year":"2006","unstructured":"Angelucci A, Gravina GL, Rucci N et al (2006) Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13(1):197\u2013210","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"9398_CR13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1677\/erc.1.00956","volume":"12","author":"N Normanno","year":"2005","unstructured":"Normanno N, De Luca A, Aldinucci D et al (2005) Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 12(2):471\u2013482","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"9398_CR14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1677\/erc.1.01185","volume":"13","author":"N Normanno","year":"2006","unstructured":"Normanno N, Gullick WJ (2006) Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer 13(1):3\u20136","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"9398_CR15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1359\/jbmr.060706","volume":"21","author":"BT Feeley","year":"2006","unstructured":"Feeley BT, Liu NQ, Conduah AH et al (2006) Mixed metastatic lung cancer lesions in bone are inhibited by Noggin overexpression and rank: Fc administration. J Bone Miner Res 21(10):1571\u20131580","journal-title":"J Bone Miner Res"},{"issue":"2","key":"9398_CR16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/(SICI)1097-0215(19980717)77:2<279::AID-IJC18>3.0.CO;2-6","volume":"77","author":"A Sasaki","year":"1998","unstructured":"Sasaki A, Kitamura K, Alcalde RE et al (1998) Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 77(2):279\u2013285","journal-title":"Int J Cancer"},{"issue":"6","key":"9398_CR17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jmicro\/52.6.503","volume":"52","author":"N Amizuka","year":"2003","unstructured":"Amizuka N, Shimomura J, Li M et al (2003) Defective bone remodelling in osteoprotegerin-deficient mice. J Electron Microsc (Tokyo) 52(6):503\u2013513","journal-title":"J Electron Microsc (Tokyo)"},{"key":"9398_CR18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3892\/ol_00000041","volume":"1","author":"K Furugaki","year":"2010","unstructured":"Furugaki K, Iwai T, Kondoh K et al (2010) Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncol Lett 1:231\u2013235","journal-title":"Oncol Lett"},{"issue":"1","key":"9398_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.cr.7290266","volume":"15","author":"JJ Yin","year":"2005","unstructured":"Yin JJ, Pollock CB, Kelly K (2005) Mechanisms of cancer metastasis to the bone. Cell Res 15(1):57\u201362","journal-title":"Cell Res"},{"issue":"1","key":"9398_CR20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm0107-25","volume":"13","author":"GD Roodman","year":"2007","unstructured":"Roodman GD (2007) Bone-breaking cancer treatment. Nat Med 13(1):25\u201326","journal-title":"Nat Med"},{"issue":"18","key":"9398_CR21","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1101\/gad.1854909","volume":"23","author":"TA Guise","year":"2009","unstructured":"Guise TA (2009) Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 23(18):2117\u20132123","journal-title":"Genes Dev"},{"issue":"6","key":"9398_CR22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00774-009-0084-4","volume":"27","author":"S Sakai","year":"2009","unstructured":"Sakai S, Takaishi H, Matsuzaki K et al (2009) 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab 27(6):643\u2013652","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"9398_CR23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S8756-3282(99)00210-0","volume":"25","author":"N Udagawa","year":"1999","unstructured":"Udagawa N, Takahashi N, Jimi E et al (1999) Osteoblasts\/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor\/RANKL but not macrophage colony-stimulating factor. Bone 25(5):517\u2013523","journal-title":"Bone"},{"issue":"51","key":"9398_CR24","doi-asserted-by":"crossref","first-page":"53848","DOI":"10.1074\/jbc.M403114200","volume":"279","author":"K Wang","year":"2004","unstructured":"Wang K, Yamamoto H, Chin JR et al (2004) Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J Biol Chem 279(51):53848\u201353856","journal-title":"J Biol Chem"},{"issue":"1","key":"9398_CR25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0003-4975(96)00220-2","volume":"62","author":"LE Quint","year":"1996","unstructured":"Quint LE, Tummala S, Brisson LJ et al (1996) Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 62(1):246\u2013250","journal-title":"Ann Thorac Surg"},{"issue":"8","key":"9398_CR26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc865","volume":"2","author":"AF Chambers","year":"2002","unstructured":"Chambers AF, Groom AC, MacDonald IC (2002) Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8):563\u2013572","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"9398_CR27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584\u2013593","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"9398_CR28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","volume":"328","author":"T Yoneda","year":"2005","unstructured":"Yoneda T, Hiraga T (2005) Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328(3):679\u2013687","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"9398_CR29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10549-004-1720-2","volume":"89","author":"G Minckwitz von","year":"2005","unstructured":"von Minckwitz G, Jonat W, Fasching P et al (2005) A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89(2):165\u2013172","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"9398_CR30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1200\/JCO.2005.08.043","volume":"23","author":"A Marchetti","year":"2005","unstructured":"Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23(4):857\u2013865","journal-title":"J Clin Oncol"},{"issue":"5","key":"9398_CR31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00428-005-1254-y","volume":"446","author":"YH Soung","year":"2005","unstructured":"Soung YH, Lee JW, Kim SY et al (2005) Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 446(5):483\u2013488","journal-title":"Virchows Arch"},{"issue":"2","key":"9398_CR32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","volume":"198","author":"S Kitazawa","year":"2002","unstructured":"Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198(2):228\u2013236","journal-title":"J Pathol"},{"issue":"1","key":"9398_CR33","first-page":"55","volume":"148","author":"N Matsuura","year":"1996","unstructured":"Matsuura N, Puzon-McLaughlin W, Irie A et al (1996) Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells. Am J Pathol 148(1):55\u201361","journal-title":"Am J Pathol"},{"issue":"12","key":"9398_CR34","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-06-4499","volume":"67","author":"Y Zhao","year":"2007","unstructured":"Zhao Y, Bachelier R, Treilleux I et al (2007) Tumor \u03b1v\u03b23 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67(12):5821\u20135830","journal-title":"Cancer Res"},{"issue":"5","key":"9398_CR35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.cad.0000127664.66472.60","volume":"15","author":"B Higgins","year":"2004","unstructured":"Higgins B, Kolinsky K, Smith M et al (2004) Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anti-cancer Drugs 15(5):503\u2013512","journal-title":"Anti-cancer Drugs"},{"issue":"6816","key":"9398_CR36","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/bmj.303.6816.1506","volume":"303","author":"NJ Bundred","year":"1991","unstructured":"Bundred NJ, Ratcliffe WA, Walker RA et al (1991) Parathyroid hormone related protein and hypercalcaemia in breast cancer. BMJ 303(6816):1506\u20131509","journal-title":"BMJ"},{"issue":"2","key":"9398_CR37","first-page":"435","volume":"7","author":"CC Bancroft","year":"2001","unstructured":"Bancroft CC, Chen Z, Dong G et al (2001) Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-\u03baB signal pathways. Clin Cancer Res 7(2):435\u2013442","journal-title":"Clin Cancer Res"},{"issue":"3","key":"9398_CR38","doi-asserted-by":"crossref","first-page":"G529","DOI":"10.1152\/ajpgi.00050.2003","volume":"285","author":"S Bamba","year":"2003","unstructured":"Bamba S, Andoh A, Yasui H et al (2003) Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol 285(3):G529\u2013G538","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"9398_CR39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.bjc.6603828","volume":"97","author":"G Lorch","year":"2007","unstructured":"Lorch G, Gilmore JL, Koltz PF et al (2007) Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. Br J Cancer 97(2):183\u2013193","journal-title":"Br J Cancer"},{"issue":"2","key":"9398_CR40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/jcp.21511","volume":"217","author":"T Yi","year":"2008","unstructured":"Yi T, Lee H-L, Cha J-H et al (2008) Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. J Cell Physiol 217(2):409\u2013422","journal-title":"J Cell Physiol"},{"issue":"1","key":"9398_CR41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2004-09-3645","volume":"106","author":"M Krampera","year":"2005","unstructured":"Krampera M, Pasini A, Rigo A et al (2005) HB-EGF\/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood 106(1):59\u201366","journal-title":"Blood"},{"issue":"10","key":"9398_CR42","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.tem.2009.06.008","volume":"20","author":"MR Schneider","year":"2009","unstructured":"Schneider MR, Sibilia M, Erben RG (2009) The EGFR network in bone biology and pathology. Trends Endocrinol Metab 20(10):517\u2013524","journal-title":"Trends Endocrinol Metab"},{"key":"9398_CR43","doi-asserted-by":"crossref","first-page":"795385","DOI":"10.1155\/2010\/795385","volume":"2010","author":"K Tamama","year":"2010","unstructured":"Tamama K, Kawasaki H, Wells A (2010) Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol 2010:795385","journal-title":"J Biomed Biotechnol"},{"issue":"2","key":"9398_CR44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165\u2013176","journal-title":"Cell"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10585-011-9398-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T21:42:17Z","timestamp":1497908537000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-011-9398-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,18]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["9398"],"URL":"https:\/\/doi.org\/10.1007\/s10585-011-9398-4","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,18]]}}}